Comparative safety and efficacy of apixaban versus warfarin in patients with end stage renal disease: Meta‐analysis

Chokesuwattanaskul, Ronpichai; Tanawuttiwat, Tanyanan; Kaewput, Wisit; Pachariyanon, Pavida; Cheungpasitporn, Wisit

doi:10.1111/pace.13393

Cited by 2 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A retrospective matched-cohort study of AF patients with ESRD found that the use of apixaban was not associated with a significant difference in the risk of stroke or systemic embolism compared to warfarin (despite a reduction in major bleeding) 119 . This finding was consistent with an earlier meta-analysis of five observational studies in patients with stage 4-5 CKD or dialysis-dependent ESRD where the use of apixaban was indicated by AF in the majority of patients (87%) 120 . Moreover, similar results are reported with rivaroxaban 121 .…”

Section: Thromboembolic Risk and Managementsupporting

confidence: 92%

Pathophysiology of atrial fibrillation and chronic kidney disease

Ding

Gupta

Wong

et al. 2020

Cardiovascular Research

View full text Add to dashboard Cite

Atrial fibrillation (AF) and chronic kidney disease (CKD) are closely related conditions with shared risk factors. The growing prevalence of both AF and CKD indicates that more patients will suffer from concurrent conditions. There are various complex interlinking mechanisms with important implications for the management of these patients. Furthermore, there is uncertainty regarding the use of oral anticoagulation in AF and CKD that is reflected by a lack of consensus between international guidelines. Therefore, the importance of understanding the implications of co-existing AF and CKD should not be underestimated. In this review, we discuss the pathophysiology and association between AF and CKD, including the underlying mechanisms, risk of thromboembolic and bleeding complications, influence on stroke management, and evidence surrounding the use of oral anticoagulation for stroke prevention.

show abstract

Section: Thromboembolic Risk and Managementsupporting

confidence: 92%